Nonvalvular atrial fibrillation can be treated with which anticoagulation options?

• A. Aspirin
• B. Warfarin
• C. DOACs only
• D. DOACs or warfarin

Answer: (D)

Nonvalvular atrial fibrillation increases the risk of stroke from clot formation in the atria, so anticoagulation is used to reduce that risk. The two main types of anticoagulants used for this purpose are warfarin (a vitamin K antagonist) and direct oral anticoagulants (DOACs), which directly inhibit thrombin or factor Xa. DOACs include drugs like dabigatran, rivaroxaban, apixaban, and edoxaban. Warfarin requires regular INR monitoring and has many drug and dietary interactions, while DOACs offer fixed dosing and typically don’t require routine blood tests, though they still need dosing adjustments for kidney function and careful consideration of bleeding risk.

Aspirin alone does not provide as strong or reliable protection against stroke in nonvalvular AF and is generally not sufficient as monotherapy for stroke prevention in this setting. Since both DOACs and warfarin are effective and approved, the best answer reflects that anticoagulation can be achieved with either class.